Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment - Trial NCT05793450
Access comprehensive clinical trial information for NCT05793450 through Pure Global AI's free database. This Phase 1 trial is sponsored by Innovent Biologics (Suzhou) Co. Ltd. and is currently Recruiting. The study focuses on Renal Impairment. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Innovent Biologics (Suzhou) Co. Ltd.
Timeline & Enrollment
Phase 1
May 05, 2023
Oct 13, 2023
Primary Outcome
Pharmacokinetics (PK): Maximum Concentration (Cmax) of IBI362,PK: Area Under the Concentration Versus Time Curve (AUC) of IBI362
Summary
The purpose of this study is to assess how fast IBI362 gets into the blood stream and how
 long it takes the body to remove it in participants with impaired kidney function compared to
 healthy participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05793450
Non-Device Trial